Objectives: We aim to elucidate causes of false-positive fetal RHD screening results obtained with cell-free DNA. Methods: Fetal RHD screening was performed in 32222 samples from RhD-negative women by multiplex real-time PCR in triplicate for RHD exons 5 and 7 using cell-free DNA isolated from maternal plasma obtained in the 27th gestational week. PCR results were compared wwith cord blood serology in 25789 pregnancies (80.04%). False-positive cases were analyzed. Known biological causes (RHD variant genes), technical causes of discordance, and errors around blood sampling were investigated with leukocyte DNA from maternal and cord blood, and cell-free DNA from stored maternal plasma. Results: Not only RHD but also Y-chromosome (DYS14) sequ...
Alloimmunization against the RhD antigen is the most common cause of hemolytic disease of the fetus ...
Non-invasive fetal RHD genotyping in Australia to reduce anti-D usage will need to accommodate both ...
Non-invasive fetal RHD genotyping in Australia to reduce anti-D usage will need to accommodate both ...
Objectives: We aim to elucidate causes of false-positive fetal RHD screening results obtained with c...
Hemolytic disease of the newborn is a clinical condition in which maternal and paternal Rh blood gro...
BACKGROUND: Fetal RHD genotyping allows targeted diagnostic testing, fetal surveillance, and eventua...
10noOBJECTIVE: This study aimed to validate non-invasive RHD genotyping of cell-free fetal DNA (cff-...
In this study, we assessed the feasibility of fetal RhD genotyping by analysis of cell-free fetal DN...
In this study, we assessed the feasibility of fetal RhD genotyping by analysis of cell-free fetal DN...
peer reviewed[en] OBJECTIVES: In some European countries, non-invasive fetal RHD genotyping is the f...
BACKGROUND: Invasive procedures to obtain fetal DNA for prenatal blood grouping present a risk to th...
Alloimmunization to antigens of Rh blood group system is of clinical relevance during pregnancy. Des...
OBJECTIVE: A non-invasive prenatal determination of the fetal RhD status might be useful for the man...
Hemolytic disease of the fetus and newborn (HDFN) is typically caused by maternal alloimmunization a...
Maternal plasma analysis for the determination of the fetal RHD status is an exciting tool for the m...
Alloimmunization against the RhD antigen is the most common cause of hemolytic disease of the fetus ...
Non-invasive fetal RHD genotyping in Australia to reduce anti-D usage will need to accommodate both ...
Non-invasive fetal RHD genotyping in Australia to reduce anti-D usage will need to accommodate both ...
Objectives: We aim to elucidate causes of false-positive fetal RHD screening results obtained with c...
Hemolytic disease of the newborn is a clinical condition in which maternal and paternal Rh blood gro...
BACKGROUND: Fetal RHD genotyping allows targeted diagnostic testing, fetal surveillance, and eventua...
10noOBJECTIVE: This study aimed to validate non-invasive RHD genotyping of cell-free fetal DNA (cff-...
In this study, we assessed the feasibility of fetal RhD genotyping by analysis of cell-free fetal DN...
In this study, we assessed the feasibility of fetal RhD genotyping by analysis of cell-free fetal DN...
peer reviewed[en] OBJECTIVES: In some European countries, non-invasive fetal RHD genotyping is the f...
BACKGROUND: Invasive procedures to obtain fetal DNA for prenatal blood grouping present a risk to th...
Alloimmunization to antigens of Rh blood group system is of clinical relevance during pregnancy. Des...
OBJECTIVE: A non-invasive prenatal determination of the fetal RhD status might be useful for the man...
Hemolytic disease of the fetus and newborn (HDFN) is typically caused by maternal alloimmunization a...
Maternal plasma analysis for the determination of the fetal RHD status is an exciting tool for the m...
Alloimmunization against the RhD antigen is the most common cause of hemolytic disease of the fetus ...
Non-invasive fetal RHD genotyping in Australia to reduce anti-D usage will need to accommodate both ...
Non-invasive fetal RHD genotyping in Australia to reduce anti-D usage will need to accommodate both ...